Citation Impact
Citing Papers
Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors
2011
Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53 -deficient cancers to mTOR inhibition
2019
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
2006 Standout
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
2009
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
2010 StandoutScience
Chemical genetics suggests a critical role for lysyl oxidase in zebrafish notochord morphogenesis
2006
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
TOR Signaling in Growth and Metabolism
2006 Standout
mTOR signaling: implications for cancer and anticancer therapy
2005
Hallmarks of Cancer: The Next Generation
2011 Standout
Antitumor activity of HER-2 inhibitors
2004
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
mTOR Signaling in Growth Control and Disease
2012 Standout
PRAS40 and PRR5-Like Protein Are New mTOR Interactors that Regulate Apoptosis
2007
Animal models of human disease: zebrafish swim into view
2007 Standout
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
The tor pathway: a target for cancer therapy
2004 Standout
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
2010 Standout
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
2011
Small-Molecule Inhibition of c-MYC:MAX Leucine Zipper Formation Is Revealed by Ion Mobility Mass Spectrometry
2012 StandoutNobel
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
2008
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
TGF-β signalling-related markers in cancer patients with bone metastasis
2008
mTOR inhibitors in the treatment of cancer
2008
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Systemic Fluorescence Imaging of Zebrafish Glycans with Bioorthogonal Chemistry
2015 StandoutNobel
Current development of mTOR inhibitors as anticancer agents
2006
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
2005
Molybdenum and Tungsten Imido Alkylidene Complexes as Efficient Olefin‐Metathesis Catalysts
2003 StandoutNobel
An ionizable lipid toolbox for RNA delivery
2021 StandoutNobel
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Targeting phosphoinositide 3-kinase—Moving towards therapy
2007
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Alkyne Metathesis: Development of a Novel Molybdenum-Based Catalyst System and Its Application to the Total Synthesis of Epothilone A and C
2001
Perturbations of the AKT signaling pathway in human cancer
2005
Targeted Molecular Therapy of GBM
2003
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
2009 StandoutNature
Intrinsic Disorder in Cell-signaling and Cancer-associated Proteins
2002
Lysosomes and autophagy in cell death control
2005
Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
2007
Recent advances in iron oxide nanocrystal technology for medical imaging☆
2006
β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
2007 StandoutNobel
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Dual Specificity Kinase DYRK3 Couples Stress Granule Condensation/Dissolution to mTORC1 Signaling
2013
Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks
2006 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Dynamics and diversity in autophagy mechanisms: lessons from yeast
2009 StandoutNobel
mTOR and cancer: insights into a complex relationship
2006
Biological determinants of endocrine resistance in breast cancer
2009
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Sprouty proteins, masterminds of receptor tyrosine kinase signaling
2008
Termination of autophagy and reformation of lysosomes regulated by mTOR
2010 StandoutNature
Matrix Elasticity Directs Stem Cell Lineage Specification
2006 Standout
Nanoparticles for the Optical Imaging of Tumor selectin
2005
Molecular mechanisms of mTOR-mediated translational control
2009 Standout
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
2009
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
In Vivo Imaging of Membrane-Associated Glycans in Developing Zebrafish
2008 StandoutScienceNobel
Superparamagnetic Iron Oxide Nanoparticles in Biomedicine: Applications and Developments in Diagnostics and Therapy
2013
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
2011
Targeting the mTOR Signaling Network for Cancer Therapy
2009
Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase
2006
Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological Applications
2008 Standout
Dissecting Temporal and Spatial Control of Cytokinesis with a Myosin II Inhibitor
2003 Science
Tissue Cells Feel and Respond to the Stiffness of Their Substrate
2005 StandoutScience
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1
2011 StandoutNobel
Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
2008
Phosphoproteomic Analysis Implicates the mTORC2-FoxO1 Axis in VEGF Signaling and Feedback Activation of Receptor Tyrosine Kinases
2013
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Differential phosphoprofiles of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts
2004
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
2009
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
2006
Sudestada1, a Drosophila ribosomal prolyl-hydroxylase required for mRNA translation, cell homeostasis, and organ growth
2014 StandoutNobel
Class 1A PI3K regulates vessel integrity during development and tumorigenesis
2008
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
2008
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
mTOR inhibition improves immune function in the elderly
2014
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
Exceedingly small iron oxide nanoparticles as positive MRI contrast agents
2017 StandoutNobel
Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice
2004
Targeted therapy for advanced renal cell carcinoma
2008
Liquid phase condensation in cell physiology and disease
2017 StandoutScience
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
2006
Works of Terence O’Reilly being referenced
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
2009
Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
2008
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
2010
MR Imaging with Ultrasmall Superparamagnetic Iron Oxide Particles in Experimental Soft-Tissue Infections in Rats
2002
Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish
2006
Inhibitors of Protein KinasesCGP 41251, a Protein Kinase Inhibitor with Potential as an Anticancer Agent
1999
Tyrosine kinase inhibitors: From rational design to clinical trials
2001
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation
2005
The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade
2005
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
2008
Antagonism of Sphingosine-1-Phosphate Receptors by FTY720 Inhibits Angiogenesis and Tumor Vascularization
2006
Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells
2004
Dual Inhibition of mTOR and Estrogen Receptor SignalingIn vitroInduces Cell Death in Models of Breast Cancer
2005
Epothilones and Their Analogs – Potential New Weapons in the Fight Against Cancer
2000